Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342249 · ClinicalTrials.gov registry record · Phase 2
Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 292
- Enrollment target
NCT02342249 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 292 participants.
The verdict
NCT02342249, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 292 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration of VX-787.
Interventions
- DRUG Placebo
- DRUG VX-787 300 mg
- DRUG VX-787 600 mg
- DRUG Oseltamivir 75 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2014-12-11 |
| Est. Completion | 2016-05-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02342249
The ClinicalTrials.gov registry entry for NCT02342249 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02342249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02342249 about?
NCT02342249 is a clinical study titled "Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects". The purpose of this study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration of VX-787.
What is the current status of trial NCT02342249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 292 participants. The study started on 2014-12-11. Estimated completion is 2016-05-25.
What interventions are being tested in trial NCT02342249?
The interventions under investigation include: Placebo (DRUG), VX-787 300 mg (DRUG), VX-787 600 mg (DRUG), Oseltamivir 75 mg (DRUG).
Who is sponsoring clinical trial NCT02342249?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.